Form 8-K

8-K — Lunai Bioworks Inc.

Accession: 0001731122-26-000871

Filed: 2026-06-17

Period: 2026-06-17

CIK: 0001527728

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — e7731_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7731_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7731_8k.htm · Sequence: 1

false

0001527728

2026-06-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange

Act of 1934

Date of Report (Date of earliest event reported): June

17, 2026

LUNAI

BIOWORKS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38758

45-2259340

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3400 Cottage Way, Suite G2,

#3256

Sacramento, California 95825

(Address of principal executive offices) (Zip Code)

+1 (424) 222-9301

(Registrant’s telephone number, including

area code)

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

LNAI

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an

emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On June 17, 2026, Lunai Bioworks, Inc. (the “Company”)

issued a letter to shareholders, which was distributed as a press release on the same day. The Company may use this letter and information

contained in it, possibly with modifications, in future presentations to current and potential investors, analysts, lenders, business

partners, acquisition candidates, customers, employees and others with an interest in the Company and its business.

A copy of the letter to shareholders is also made

available on the Company’s website at ir.lunaibioworks.com. Materials on the Company’s website are not part of or incorporated

by reference into this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed with this Current Report on Form 8-K:

Exhibit Number

Description

99.1

Lunai Bioworks, Inc. Press Release providing Letter to Shareholders, dated June 17, 2026

104

Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LUNAI BIOWORKS, INC.

By:

Name:

David Weinstein

Date: June 17, 2026

Title:

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7731_ex99-1.htm · Sequence: 2

EXHIBIT

99.1

LUNAI BIOWORKS: CEO LETTER

TO SHAREHOLDERS

SACRAMENTO, Calif., June 17, 2026

Fellow Shareholders,

Over the past several months, Lunai Bioworks (NASDAQ:

LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence,

and national security and biology. I would like to update you on developments that have substantially strengthened our position and created

multiple pathways for shareholder value creation.

A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM

In April 2026, we secured our first revenue-generating,

multi-year defense collaboration through BioSymetrics to deploy our AI-enabled platform for chemical threat assessment. This contract

represents not a research relationship but an active commercial engagement with the U.S. government.

Beyond that initial contract, we have established

the Pathfinder Consortium—a national alliance of leading institutions including Harvard University, Brigham and Women’s Hospital

(led by Dr. Calum MacRae), the University of Utah, Purdue University, and the University of Colorado. These partnerships reflect the scientific

rigor and national security relevance of our approach.

Looking forward to the second half of 2026 we believe

our Augusta platform which combines Contingent AI, large toxicity databases, and in vivo testing aligns with the priorities outlined in

the 2027 Defense Authorization Bill published this month. It specifically calls for the nation “to develop a strategy to leverage

artificial intelligence-enabled and high-throughput biological screening approaches in support of identifying and characterizing potential

chemical neurotoxic threat agents”. This is precisely what we are doing under our current contract and further involves the capabilities

we now have with the Pathfinder Consortium.

PRECISION NEUROLOGY: A COMPLEMENTARY GROWTH ENGINE

In parallel, Lunai continues to advance its precision

neurology pipeline through our Augusta™ AI platform in Epilepsy, Parkinsons, and Alzheimer’s. We recently announced and are

advancing collaborations including a partnership with BrainStorm Therapeutics supported by foundation funding, and we continue to benefit

from NIH-supported research initiatives, including a Phase I/II STTR grant ($1.85 million awarded to BioSymetrics) for alcohol use disorder

research. These partnerships represent external validation of our biology-first discovery approach.

Neurological diseases remain among the most challenging

and costly medical conditions, affecting millions of patients worldwide. By combining large-scale patient datasets with advanced AI analytics

and validated with in vivo testing, we are identifying therapeutic opportunities that conventional methods miss. This work represents

a significant long-term value driver for Lunai, and one that is independent of our biodefense activities.

THE CONVERGENCE: AI, BIOTECHNOLOGY, AND THE FULL SPECTRUM OF BIOLOGICAL

THREATS

The strategic importance of biodefense is increasingly

recognized by governments, scientists, and technology leaders worldwide.

Recently, the chief executives of Anthropic, OpenAI,

Google DeepMind, and Microsoft AI, alongside numerous leaders from biotechnology and national security organizations, signed a public

letter supporting enhanced safeguards around synthetic DNA and nucleic acid synthesis technologies. The letter highlights a fundamental

concern: advances in artificial intelligence are rapidly reducing barriers to the design and engineering of biological agents.

This is not theoretical. The risks are dual: engineered

biological threats from state and non-state actors, and the accelerating risk of novel pandemics—whether natural or human-engineered.

The line between public health preparedness and national security has blurred entirely. COVID demonstrated the global health and economic

cost of a biological event. The prospect of deliberate bioweapon creation through synthetic biology represents an equally grave but far

less recognized threat.

Governments are responding. The recognition that the

next biological crisis—pandemic or weaponized—could originate from either natural evolution or deliberate engineering is driving

substantial investment in detection, identification, and countermeasure development at speeds and scales previously reserved for kinetic

warfare.

Lunai’s current biodefense activities focus

on chemical threat assessment through our first revenue-generating defense contract and the Pathfinder Consortium. However, our AI-driven

platform for threat identification, phenotypic screening, and countermeasure discovery is directly applicable across the full spectrum

of biological threats—both pandemic and weaponized. We are actively exploring partnerships and opportunities to expand our biodefense

capabilities into biological threat detection and countermeasure development. Given the government’s growing recognition of both

pandemic and bioweapon risks, and our existing partnerships with leading scientific institutions and federal agencies, we believe we are

well-positioned to participate in what will become a major national security and public health priority.

PROTECTING SHAREHOLDER VALUE: LITIGATION AS VALUE UNLOCK

As we continue to execute and announce meaningful

milestones, we have observed trading activity that does not reflect the progress being achieved by Lunai.

In May 2026, we initiated legal action in the U.S.

District Court for the District of Delaware against unidentified parties alleged to have engaged in naked short selling and related manipulative

trading. The evidence was substantial: anomalous failing-to-deliver of 29.6 million shares (81.6% of all outstanding shares), with peak

trading volumes on March 17, 2026, reaching 554 million shares—15.3 times all outstanding shares in a single day.

Critically, the Court found good cause for expedited

discovery and established a prima facie basis for our claims. This rule permits us to obtain trading records from broker-dealers, custodians,

and market participants to identify those responsible. We are now in the discovery process.

The purpose of this litigation is straightforward:

identify the parties engaged in improper market activity, hold them accountable, and restore shareholder value that has been artificially

suppressed. Litigation discovery will force disclosure of positions, trading records, and brokerage relationships that shorts depend on

keeping hidden. As those identities emerge, regulatory scrutiny of the short positions themselves becomes inevitable—and expensive

to maintain.

We intend to pursue this matter vigorously. In our

view, protecting shareholder interests and pursuing accountability for market manipulation is not a distraction, it is a core responsibility

of management.

LOOKING FORWARD

Lunai today is substantially different from the company

it was a year ago. We have established the first revenue-generating defense contract, assembled a national network of world-class scientific

and military partners, continued to validate our AI-driven approach in both biodefense and precision neurology, and initiated legal action

to address market manipulation artificially suppressing our stock price.

The convergence of AI, biotechnology, and national

security is creating a rare strategic opportunity. Through our biodefense platform and precision neurology pipeline, we are building a

company positioned to address some of the largest and most important markets, backed by government partners and validated by leading scientific

institutions.

As we move through the second half of 2026, our focus

remains clear: advancing and expanding our biodefense platform, neurology programs, executing our litigation strategy, and continuing

to validate our platform across both healthcare and national security applications. Now that the company has achieved compliance with

the NASDAQ listing requirements we are positioned to build long term value for our shareholders.

I would like to thank you for your continued support.

Sincerely,

David Weinstein

Chief Executive Officer

Lunai Bioworks, Inc.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 17, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 17, 2026

Entity File Number

001-38758

Entity Registrant Name

LUNAI

BIOWORKS, INC.

Entity Central Index Key

0001527728

Entity Tax Identification Number

45-2259340

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3400 Cottage Way

Entity Address, Address Line Two

Suite G2

Entity Address, Address Line Three

#3256

Entity Address, City or Town

Sacramento

Entity Address, State or Province

Entity Address, Postal Zip Code

95825

City Area Code

(424)

Local Phone Number

222-9301

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

LNAI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration